Key questions employers should ask their PBM about GLP-1s As oral GLP-1s join formularies, employers should be discussing these key questions with their PBM, looking beyond coverage decisions to what will truly drive outcomes: Patient selection: How do you identify clinically appropriate candidates, not just anyone requesting treatment
This is particularly important when we need to verify the integration of the syringe in delivery devices such as auto-injectors
Most researchers report that cardiac awareness diminishes significantly after 6 months of stable dosing
Glucagon receptor activity is one of the features that separates retatrutide from earlier options, because it may widen the treatment's effect on energy balance
Like all medications, it carries the risk of side effects, ranging from mild gastrointestinal disturbances to more serious concerns such as pancreatitis and thyroid C-cell tumors in animal studies
Cholesterol crystallization in model biles: effects of bile salt and phospholipid species composition